Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1044 NORTH U.S. HIGHWAY ONE, SUITE 201 JUPITER FL 33477 |
Tel: | N/A |
Website: | https://dyadic.com |
IR: | See website |
Key People | ||
Mark A. Emalfarb President, Chief Executive Officer, Director | Ping Wang Rawson Chief Financial Officer | Joseph Hazelton Chief Operating Officer |
Doug Pace Executive Vice President - Business Development | Ronen Tchelet Vice President of Research and Business Development |
Business Overview |
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications. |
Financial Overview |
For the fiscal year ended 31 December 2023, Dyadic International Inc revenues decreased 1% to $2.9M. Net loss decreased 30% to $6.8M. Revenues reflect Research and Development Revenue decrease of 87% to $353K. Lower net loss reflects Research and Development - Balancing val decrease of 24% to $3.3M (expense), Stock-based Compensation in SGA decrease of 28% to $1.2M (expense), Interest Income increase from $180K to $417K (income). |
Employees: | 7 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $35.13M as of Dec 31, 2023 |
Annual revenue (TTM): | $2.90M as of Dec 31, 2023 |
EBITDA (TTM): | -$8.19M as of Dec 31, 2023 |
Net annual income (TTM): | -$6.80M as of Dec 31, 2023 |
Free cash flow (TTM): | -$6.73M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 29,236,814 as of Apr 17, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |